PE Tech Report


Like this article?

Sign up to our free newsletter

OrbiMed Launches USD950m VC fund

OrbiMed has held the closing of its next venture capital fund, OrbiMed Private Investments VI, LP, with USD950 million in limited partner commitments.

Investors in the fund include some of the preeminent medical research institutions globally, along with leading endowments, foundations and sovereign wealth funds.
Consistent with its predecessor funds, the new fund will invest in all stages and sectors of the healthcare industry, with a focus on biopharmaceuticals, medical devices, diagnostics and healthcare IT companies located in North America and Europe. The new fund is expected to invest in approximately 30 portfolio companies in amounts generally ranging from USD10 million to USD75 million.
Carl Gordon, a Partner at OrbiMed and Co-Head of Global Private Equity, says: “The increasing pace of translation of science to medicine creates exciting opportunities for the Fund in areas such as oncology, central nervous system disease, and gene editing.”
“With this Fund we plan to accelerate our collaborations with leading life sciences entrepreneurs, strategic companies, research institutions and physicians, to drive the creation of novel therapies that address unmet medical needs,” says Jonathan Silverstein, also an OrbiMed Partner and Co-Head of Global Private Equity.

Like this article? Sign up to our free newsletter